Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование
Investment in child and adolescent health and development : key messages from Disease Control Priorities, 3rd Edition. / Disease Control Priorities-3 Child and Adolescent Health and Development Authors Group.
в: The Lancet, Том 391, № 10121, 17.02.2018, стр. 687-699.Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование
}
TY - JOUR
T1 - Investment in child and adolescent health and development
T2 - key messages from Disease Control Priorities, 3rd Edition
AU - Disease Control Priorities-3 Child and Adolescent Health and Development Authors Group
AU - Bundy, Donald A.P.
AU - de Silva, Nilanthi
AU - Horton, Susan
AU - Patton, George C.
AU - Schultz, Linda
AU - Jamison, Dean T.
AU - Abubakara, Amina
AU - Ahuja, Amrita
AU - Alderman, Harold
AU - Allen, Nicolas
AU - Appleby, Laura
AU - Aurino, Elisabetta
AU - Azzopardi, Peter
AU - Baird, Sarah
AU - Banham, Louise
AU - Behrman, Jere
AU - Benzian, Habib
AU - Bhalotra, Sonia
AU - Bhutta, Zulfiqar
AU - Black, Maureen
AU - Bloem, Paul
AU - Bonell, Chris
AU - Bradley, Mark
AU - Brinkman, Sally
AU - Brooker, Simon
AU - Burbano, Carmen
AU - Burnett, Nicolas
AU - Cernuschi, Tania
AU - Clarke, Sian
AU - Coffey, Carolyn
AU - Colenso, Peter
AU - Croke, Kevin
AU - Daniels, Amy
AU - De la Cruz, Elia
AU - de Walque, Damien
AU - Deolaikar, Anil
AU - Drake, Lesley
AU - Fernald, Lia
AU - Fernandes, Meena
AU - Fernando, Deepika
AU - Fink, Günther
AU - Galloway, Rae
AU - Gelli, Aulo
AU - Georgiadis, Andreas
AU - Gitonga, Caroline
AU - Giyosa, Boitshepo
AU - Glewwe, Paul
AU - Gona Nzovu, Joseph
AU - Gove, Amber
AU - Grigorenko, Elena
PY - 2018/2/17
Y1 - 2018/2/17
N2 - The realisation of human potential for development requires age-specific investment throughout the 8000 days of childhood and adolescence. Focus on the first 1000 days is an essential but insufficient investment. Intervention is also required in three later phases: the middle childhood growth and consolidation phase (5–9 years), when infection and malnutrition constrain growth, and mortality is higher than previously recognised; the adolescent growth spurt (10–14 years), when substantial changes place commensurate demands on good diet and health; and the adolescent phase of growth and consolidation (15–19 years), when new responses are needed to support brain maturation, intense social engagement, and emotional control. Two cost-efficient packages, one delivered through schools and one focusing on later adolescence, would provide phase-specific support across the life cycle, securing the gains of investment in the first 1000 days, enabling substantial catch-up from early growth failure, and leveraging improved learning from concomitant education investments.
AB - The realisation of human potential for development requires age-specific investment throughout the 8000 days of childhood and adolescence. Focus on the first 1000 days is an essential but insufficient investment. Intervention is also required in three later phases: the middle childhood growth and consolidation phase (5–9 years), when infection and malnutrition constrain growth, and mortality is higher than previously recognised; the adolescent growth spurt (10–14 years), when substantial changes place commensurate demands on good diet and health; and the adolescent phase of growth and consolidation (15–19 years), when new responses are needed to support brain maturation, intense social engagement, and emotional control. Two cost-efficient packages, one delivered through schools and one focusing on later adolescence, would provide phase-specific support across the life cycle, securing the gains of investment in the first 1000 days, enabling substantial catch-up from early growth failure, and leveraging improved learning from concomitant education investments.
UR - http://www.scopus.com/inward/record.url?scp=85034088393&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(17)32417-0
DO - 10.1016/S0140-6736(17)32417-0
M3 - Review article
C2 - 29153316
AN - SCOPUS:85034088393
VL - 391
SP - 687
EP - 699
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10121
ER -
ID: 62763036